

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,846,799  
DATED : January 25, 2005  
INVENTOR(S) : Jay A. Nadel, Kiyoshi Takeyama

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

**On the Cover Page**

Page 1, in the first column, line 15, **delete** "This patent is subject to a terminal disclaimer".

Page 1, in the second column, line 14, the word "Epithelial" should be -- Epithelial --.

Page 2, in the second column, line 18, the word "national" should be -- National --.

**In the Figures**

In Figure 16, the words "Stain d Ar a f Epith lium" should be-- Stained Area of Epithelium --.

In Figure 17, the words "Stain d Ar a f Epith lium" should be-- Stained Area of Epithelium --.

**In the Specification**

In column 1, line 50, the word "dearance" should be -- clearance --.

In column 1, line 51, the word "partides" should be -- particles --.

In column 3, line 52, the word "TGF" should be -- TGF- $\alpha$  --.

In column 3, line 52, the word "EGF-R" should be -- EGF-R. --.

In column 4, line 41, the word -- on -- should be inserted after the work "instillation".

In column 5, line 46, the word "cytokineactivated" should be -- cytokine-activated --.

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, CA 94303

PATENT NO: 6,846,799

No. of add'l copies  
@ 50¢ per page

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,846,799  
DATED : January 25, 2005  
INVENTOR(S) : Jay A. Nadel, Kiyoshi Takeyama

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In column 7, line 4, the word "hergulin" should be -- heregulin --.

In column 7, line 55, the word "MP" should be -- MMP --.

In column 9, line 11, the word "alterative" should be -- alternative --.

In column 11, line 50, the words "super oxide" should be -- superoxide --.

In column 13, line 65, the word "deavage" should be -- cleavage --.

In column 15, line 24, the word "heterocydic" should be -- heterocyclic --.

In column 15, line 35, the word "oligonudeotide" should be -- oligonucleotide --.

In column 15, line 59, the word "oligonudeotides" should be -- oligonucleotides--.

In column 18, line 6, the word "bronchidilators" should be -- bronchiodilators --.

In column 18, line 45, the word "Lasty" should be -- Lastly --.

In column 19, line 58, the word "partides" should be -- particles --.

In column 25, line 16, the word "mm" should be --  $\mu\text{m}$  --.

In column 25, line 59, the word "epfthelium" should be -- epithelium --.

In column 36, line 60, the word "instillatin" should be -- instillation --.

In column 50, line 43, the word "TNF" should be --  $\text{TNF}\alpha$  --.

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, CA 94303

PATENT NO: 6,846,799

No. of add'l copies  
@ 50¢ per page

Filed Electronically on:  
August 8, 2008

<b>PETITION FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322 FOR PATENT AND TRADEMARK OFFICE ERROR</b>  Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket Number	UCSF-085CIP
	First Named Inventor	JAY A. NADEL
	Application Number	09/616,223
	Filing Date	July 14, 2000
	Patent Number	6,846,799
	Issue Date	January 25, 2005
	Title	PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS

Sir:

Applicants petition under 37 C.F.R. § 1.322 for a Certificate of Correction to correct errors in the claims for the above-identified patent due to Patent and Trademark Office error.

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. Please make the following corrections:

**On the Cover Page**

Page 1, in the first column, line 15, **delete** “This patent is subject to a terminal disclaimer”.

Page 1, in the second column, line 14, the word “Epithelial” should be -- Epithelial --.

Page 2, in the second column, line 18, the word “national” should be -- National --.

**In the Figures**

In Figure 16, the words “Stain d Ar a f Epith lium” should be-- Stained Area of Epithelium --.

In Figure 17, the words “Stain d Ar a f Epith lium” should be-- Stained Area of Epithelium --.

**In the Specification**

In column 1, line 50, the word “dearance” should be -- clearance --.

In column 1, line 51, the word “partides” should be -- particles --.

In column 3, line 52, the word “TGF” should be -- TGF- $\alpha$  --.

In column 3, line 52, the word “EGF-R” should be -- EGF-R. --.

In column 4, line 41, the word -- on -- should be inserted after the work “instillation”.

In column 5, line 46, the word “cytokineactivated” should be -- cytokine-activated --.

In column 7, line 4, the word “hergulin” should be -- heregulin --.

In column 7, line 55, the word “MP” should be -- MMP --.

In column 9, line 11, the word “alterative” should be -- alternative --.

In column 11, line 50, the words “super oxide” should be -- superoxide --.

In column 13, line 65, the word “deavage” should be -- cleavage --.

In column 15, line 24, the word “heterocyclic” should be -- heterocyclic --.

In column 15, line 35, the word “oligonudeotide” should be -- oligonucleotide --.

In column 15, line 59, the word “oligonudeotides” should be -- oligonucleotides--.

In column 18, line 6, the word “bronchidilators” should be -- bronchiodilators --.

In column 18, line 45, the word “Lasty” should be -- Lastly --.

In column 19, line 58, the word “partides” should be -- particles --.

In column 25, line 16, the word “mm” should be --  $\mu\text{m}$  --.

In column 25, line 59, the word “epfthelium” should be -- epithelium --.

In column 36, line 60, the word “instillatin” should be -- instillation --.

In column 50, line 43, the word “TNF□” should be -- TNF $\alpha$  --.

#### Comments regarding “Terminal Disclaimer”

As noted above, Applicants request that page 1 of the instant patent be amended to delete “This patent is subject to a terminal disclaimer.”

On September 27, 2001, a response to the Restriction Requirement mailed August 28, 2001 was filed. The September 27, 2001 response included a two-page response, and a two-page transmittal. The document description on PAIR for the response portion of the September 27, 2001 response is “Amendment After Non-Final Rejection.” The document description on PAIR for the first page of the transmittal is “Miscellaneous Incoming Letter.” The document description on PAIR for the second page of the transmittal is “Terminal Disclaimer.”

No Terminal Disclaimer was filed in this application. As such, the sentence “This patent is subject to a terminal disclaimer” on page 1 of the instant patent is an error.

Applicants submit that the erroneous labeling of the second page of the aforementioned transmittal as a “Terminal Disclaimer” is the source of the error. As such, the error was made by the Patent Office. Applicants thus respectfully request deletion of the sentence “This patent is subject to a terminal disclaimer” from page 1 of the instant patent.

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: August 8, 2008

By: /Paula A. Borden, Reg.# 42344/  
Paula A. Borden  
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, CA 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231